In esophageal cancers, Kato et al. [190] demonstrated with a series of in vivo and in vitro models that IL-6 mediates both the CAFs suppression of CD8+ and the promotion of FoxP3+ tumor-infiltrating lymphocytes, resulting in experimental blockage of IL-6, suggesting a promising efficacy of immunotherapy. This evidence concerns the gene CD8A and neoplasm.